NCT06242834View on ClinicalTrials.gov

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

April 24, 2027

Study Completion Date

November 24, 2028

Conditions
B-Cell Non-Hodgkin Lymphoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Echocardiography

Undergo echocardiography

BIOLOGICAL

Pembrolizumab

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET scan

DRUG

Tazemetostat

Given PO

Trial Locations (1)

60611

RECRUITING

Northwestern University, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER